Clinical TrialsIdorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Idorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Read Post »
Clinical TrialsPersonalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Personalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Read Post »
Clinical TrialsIdorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Idorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Read Post »
Clinical TrialsNovartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Novartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Read Post »
New Drug ApprovalShionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Shionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Read Post »
Clinical TrialsBioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC BioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC Read Post »
Clinical TrialsReplimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Replimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Read Post »
Clinical TrialsASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... ASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... Read Post »
Clinical TrialsLilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Lilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Read Post »
Clinical TrialsAkeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Akeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Read Post »
Clinical TrialsApalutamide Plus ADT Delivers Landmark Phase 3 Results in High‑Risk Local... Apalutamide Plus ADT Delivers Landmark Phase 3 Results in High‑Risk Local... Read Post »
Clinical TrialsCogent’s PEAK Trial Shows Significant Survival Benefit in KIT-Driven GIST Cogent’s PEAK Trial Shows Significant Survival Benefit in KIT-Driven GIST Read Post »
Clinical TrialsIncyte’s frontMIND Trial Delivers Positive Phase 3 Results in High-Risk D... Incyte’s frontMIND Trial Delivers Positive Phase 3 Results in High-Risk D... Read Post »
Clinical TrialsPfizer’s TALAPRO-3 Trial Shows Strong Benefit for TALZENNA Plus XTAND... Pfizer’s TALAPRO-3 Trial Shows Strong Benefit for TALZENNA Plus XTAND... Read Post »
Clinical TrialsImmunome’s Varegacestat Cuts Risk of Desmoid Tumor Progression by 84% in ... Immunome’s Varegacestat Cuts Risk of Desmoid Tumor Progression by 84% in ... Read Post »
Clinical TrialsFirst-Line RYBREVANT Plus LAZCLUZE Shows Sustained Survival in Atypical EGF... First-Line RYBREVANT Plus LAZCLUZE Shows Sustained Survival in Atypical EGF... Read Post »
New Drug ApprovalFDA Approves First Inhaled Mealtime Insulin for Pediatric Diabetes FDA Approves First Inhaled Mealtime Insulin for Pediatric Diabetes Read Post »
Clinical TrialsDizal’s Sunvozertinib Outperforms Chemotherapy in WU-KONG28 Trial Dizal’s Sunvozertinib Outperforms Chemotherapy in WU-KONG28 Trial Read Post »
New Drug ApprovalFDA Approves Wockhardt’s ZAYNICH; India Also Grants Authorization FDA Approves Wockhardt’s ZAYNICH; India Also Grants Authorization Read Post »
Clinical TrialsPfizer Reports Landmark Seven-Year Results for LORBRENA in ALK-Positive NSC... Pfizer Reports Landmark Seven-Year Results for LORBRENA in ALK-Positive NSC... Read Post »
Clinical TrialsAstraZeneca’s Anselamimab Shows Survival Benefit in Kappa AL Amyloidosis,... AstraZeneca’s Anselamimab Shows Survival Benefit in Kappa AL Amyloidosis,... Read Post »
New Drug ApprovalEuropean Commission Authorizes New VENCLYXTO Regimens for CLL European Commission Authorizes New VENCLYXTO Regimens for CLL Read Post »
Clinical TrialsMajesTEC‑9 Confirms TECVAYLI Survival Benefit in Relapsed Multiple Myelom... MajesTEC‑9 Confirms TECVAYLI Survival Benefit in Relapsed Multiple Myelom... Read Post »
Clinical TrialsFDA Updates TREMFYA Label With Structural Joint Damage Data in PsA FDA Updates TREMFYA Label With Structural Joint Damage Data in PsA Read Post »
New Drug ApprovalImfinzi Cuts Recurrence Risk by 32% and Wins FDA Approval in High-Risk NMIB... Imfinzi Cuts Recurrence Risk by 32% and Wins FDA Approval in High-Risk NMIB... Read Post »
Clinical TrialsFDA Prioritizes Review of Zydus’ Saroglitazar for Rare Liver Disease FDA Prioritizes Review of Zydus’ Saroglitazar for Rare Liver Disease Read Post »
Clinical TrialsZanidatamab–Tislelizumab Triplet Delivers Practice‑Changing Survival Ga... Zanidatamab–Tislelizumab Triplet Delivers Practice‑Changing Survival Ga... Read Post »
Clinical TrialsNervGen Reports Neural Recovery Signals With NVG-291 in Chronic SCI Trial NervGen Reports Neural Recovery Signals With NVG-291 in Chronic SCI Trial Read Post »
Clinical TrialsImmutep Links Eftilagimod Alfa Immune Activation to Survival Benefit Across... Immutep Links Eftilagimod Alfa Immune Activation to Survival Benefit Across... Read Post »
Clinical TrialsOno Reports Encouraging Phase 2 Results for ONO-2808 in MSA Ono Reports Encouraging Phase 2 Results for ONO-2808 in MSA Read Post »
Clinical TrialsIpsen Presents New Data Reinforcing IQIRVO® in PBC at EASL 2026 Ipsen Presents New Data Reinforcing IQIRVO® in PBC at EASL 2026 Read Post »
Clinical TrialsGSK’s Bepirovirsen Achieves Functional Cure in Phase 3 CHB Trials GSK’s Bepirovirsen Achieves Functional Cure in Phase 3 CHB Trials Read Post »
New Drug ApprovalIronwood and AbbVie Secure FDA Expansion for LINZESS in Young Children for ... Ironwood and AbbVie Secure FDA Expansion for LINZESS in Young Children for ... Read Post »
New Drug ApprovalFDA Clears AbbVie’s DECNUPAZ as First CD123 ADC for BPDCN FDA Clears AbbVie’s DECNUPAZ as First CD123 ADC for BPDCN Read Post »
Clinical TrialsAligos Shows Long-Term Pevifoscorvir Activity in Chronic HBV Aligos Shows Long-Term Pevifoscorvir Activity in Chronic HBV Read Post »
Clinical TrialsArrowhead Reports Liver Fat Reduction With ARO-INHBE in Obesity and MASH Arrowhead Reports Liver Fat Reduction With ARO-INHBE in Obesity and MASH Read Post »
Clinical TrialsBiohaven Shows Early Clinical Gains in Graves’ Disease and IgAN Biohaven Shows Early Clinical Gains in Graves’ Disease and IgAN Read Post »
Clinical TrialsAltimmune Reports Strong Fibrosis Improvements With Pemvidutide in MASH Altimmune Reports Strong Fibrosis Improvements With Pemvidutide in MASH Read Post »
Clinical TrialsGilead Presents Long-Term Livdelzi Phase 3 Results at EASL 2026 Gilead Presents Long-Term Livdelzi Phase 3 Results at EASL 2026 Read Post »
Clinical TrialsIdefirix Advances Toward Full EU Approval After Positive PAES Results Idefirix Advances Toward Full EU Approval After Positive PAES Results Read Post »
Clinical TrialsLIB Showcases Long-Term LEROCHOL® Data at EAS 2026 LIB Showcases Long-Term LEROCHOL® Data at EAS 2026 Read Post »
Clinical TrialsSobi Reports 85% Lower Pancreatitis Risk with Olezarsen in sHTG Sobi Reports 85% Lower Pancreatitis Risk with Olezarsen in sHTG Read Post »
New Drug ApprovalApotex Wins Health Canada Approval for IHEEZO Eye Anesthetic Gel Apotex Wins Health Canada Approval for IHEEZO Eye Anesthetic Gel Read Post »
Clinical TrialsKura Reports Encouraging Responses in KRAS G12C Cancers at ASCO 2026 Kura Reports Encouraging Responses in KRAS G12C Cancers at ASCO 2026 Read Post »
Clinical TrialsBiohaven’s Opakalim Nears Regulatory Filing as Biohaven Reports New Epile... Biohaven’s Opakalim Nears Regulatory Filing as Biohaven Reports New Epile... Read Post »
Clinical TrialsDyne Therapeutics Files BLA for DYNE‑251 in DMD Dyne Therapeutics Files BLA for DYNE‑251 in DMD Read Post »
ResearchNovo Nordisk Presents New Data on Residual Cardiovascular Inflammation Novo Nordisk Presents New Data on Residual Cardiovascular Inflammation Read Post »
New Drug ApprovalVyepti Wins South Korea Approval for Adult Migraine Vyepti Wins South Korea Approval for Adult Migraine Read Post »
Clinical TrialsLilly’s VERVE-102 Cuts LDL-C by Up to 62% in Phase 1b Heart-2 Study Lilly’s VERVE-102 Cuts LDL-C by Up to 62% in Phase 1b Heart-2 Study Read Post »
New Drug ApprovalEC Approves Pharming’s Joenja for Activated PI3K Delta Syndrome EC Approves Pharming’s Joenja for Activated PI3K Delta Syndrome Read Post »
